Longevity: Senotherapy for Parkinson's Disease

The aging brain’s slippery slope
 As we age, brain cells accumulate damage, become less efficient, and in some cases, enter a state of neither being alive nor dead, known as senescence.

Understanding the biology of these senescent cells - what drives them, how they harm surrounding tissue, and how to eliminate them — may hold the key to changing the course of Parkinson’s disease.

Parkinson’s disease is a progressive brain disorder that affects the brain globally, but is best known for its effect on movements. Despite advances in symptom control, there remains no cure, and no therapy that protects or regenerates the dying neurons.

At the center of this illness is a group of dopamine-producing neurons. These cells help control movement, and when they begin to die off, the result is tremors, stiffness, slow movement, and a range of non-motor problems like depression, sleep disturbances, digestive issues, and even hallucinations.

While several medications exist to reduce symptoms, most notably L-DOPA, which temporarily boosts dopamine levels, none of them prevent the progressive loss of these neurons.

This decline is not just frustrating—it reflects a deeper biological issue: the treatments do not stop the actual disease process.

Why dopamine neurons are easy targets
Getting older is the biggest risk factor for developing Parkinson’s disease. As we age, it’s normal for the brain to lose some neurons and for movement to slow down a bit.

But Parkinson’s goes beyond normal aging. It causes specific types of damage and leads to the buildup of harmful proteins that are not typically found in healthy older brains.

The brain cells that make dopamine (located in a small area called the substantia nigra) are especially vulnerable. These cells have long, branching connections that reach many other parts of the brain. That makes them very powerful, but also very demanding.

They need a lot of energy to keep working, and they constantly use calcium to send signals. Unfortunately, they’re not good at handling too much calcium, which can become toxic and damage the cell from within.

On top of that, these dopamine cells face something called oxidative stress. This happens when harmful molecules, known as reactive oxygen, build up faster than the brain can remove them. These molecules can damage the cell’s structure, including its DNA and energy systems. Oxidative stress is a major part of both aging and Parkinson’s.

Dopamine itself adds to the problem. When dopamine is broken down inside the cell, it naturally creates some of these harmful molecules. In a healthy brain, antioxidants like glutathione keep things under control. But in Parkinson’s, these protective systems are weakened, especially glutathione, which is found in much lower amounts in affected brain areas.

As a result, the cells can’t clear out the damage. Their energy factories, the mitochondria, begin to fail, creating even more stress and pushing the cells closer to death.

Over time, all these pressures pile up. The dopamine cells start to shut down, and the brain loses its ability to control movement, balance, and coordination—the main symptoms of Parkinson’s disease.

Protein traffic jam
A signature feature of Parkinson’s disease is the presence of clumped proteins inside brain cells. These are known as Lewy bodies and are primarily made up of a misfolded protein called alpha-synuclein.

In normal neurons, the protein called alpha-synuclein helps with the release of neurotransmitters. But in Parkinson’s, it misfolds and aggregates into toxic structures that gradually fill the brain cells and interfere with essential cellular functions.

These aggregates spread from cell to cell (much like infectious prions). They trigger a domino effect in which healthy alpha-synuclein gets pulled into misfolded chains, accelerating the spread of damage.

Cells normally rely on quality control systems to clean up misfolded proteins. But in Parkinson’s, these systems are impaired. Proteins accumulate without being cleared, and autophagosomes, designated garbage-cleaning cells, fail to digest harmful aggregates.

Senescence: when cells stop working but won’t die
A growing body of research shows that cellular senescence plays a major role in the development and progression of Parkinson’s disease.

Senescent cells are cells that have stopped dividing in response to damage or stress but remain metabolically active. But instead of dying, they stay alive and secrete a stew of harmful molecules: pro-inflammatory cytokines, enzymes, and growth factors, collectively known as the senescence-associated secretory phenotype, SASP. They are like destructive zombie neurons.

In the brain, senescence occurs in dopamine neurons as well as in astrocytes and microglia. Senescent astrocytes (the brain's supporting cells) lose their ability to support neurons and instead release toxins that worsen oxidative stress. Senescent microglia (the brain's immune cells) become overactive and promote chronic inflammation. Together, they contribute to a toxic environment that accelerates the death of dopamine neurons.

In experimental models, clearing senescent cells can delay disease progression, protect dopamine neurons, and improve motor function. This has opened a new therapeutic direction: targeting senescent cells to slow or halt the disease.

New treatments target senescence
Because traditional treatments like L-DOPA only manage symptoms without affecting disease progression, scientists are now focusing on drugs that eliminate or suppress senescent cells.

These include senolytics, which selectively kill senescent cells, and senomorphics, which block their harmful secretions without killing them.

Natural compounds like curcumin and fisetin have shown great promise. Curcumin, found in turmeric (but you will need a lot ..), reduces oxidative stress and inflammation, prevents alpha-synuclein clumping, and protects dopamine neurons in various models of Parkinson’s disease. Fisetin, found in fruits like strawberries (in low doses, a daily bowl of strawberries is not enough), works through similar mechanisms and has extended lifespan in aging mice while reducing signs of cellular senescence.

Astragaloside IV, a compound derived from a traditional Chinese herb, has also shown protective effects by promoting the removal of damaged mitochondria in astrocytes, preventing their entry into a senescent state.

Challenges in senescence-based therapy
Despite the excitement, there are important hurdles to overcome.

Senescent cells are diverse, and no single biomarker can reliably identify them across all tissues. Moreover, senescent cells also play beneficial roles in wound healing and tumor suppression. Removing them indiscriminately could interfere with these vital processes.

Further, many senotherapeutic compounds have only been tested for short durations in animals, and their long-term safety in humans is unknown.

Some treatments, like rapamycin, have shown both positive and negative effects, depending on the dose and context. Intermittent dosing may help reduce risks, but this strategy needs careful validation.

Senomorphics, which suppress harmful secretions rather than kill the cells, may offer a safer alternative for long-term use, although some still carry side effects.

To move forward, researchers are designing next-generation therapies with greater specificity and fewer side effects. These include peptide-based drugs, advanced nanoparticles, targeted immunotherapies, and so-called senoreverters—experimental cocktails that might reprogram senescent cells to behave more like youthful ones. While most of these have not yet been tested in Parkinson’s models, their potential is clear.

The new wave of Parkinson’s treatments may not only target the symptoms but finally go after the underlying mechanisms—cellular stress, misfolded proteins, and the toxic effects of aging cells.

By shifting focus from patching up the damage to stopping it at the source, these therapies could redefine how we approach age-related brain diseases in the years to come.

That's really good news for the world's millions of parkinsons patients!

About the paper that inspired:

First Author: David J. Rademacher, USA
Published: Biomedicines, June 2025
Link to paper: https://www.mdpi.com/2227-9059/13/6/1400

Pssst - remember to subscribe to our free newsletter!